Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05125016
Title REGN4336 (a PSMAXCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab in Adult Male Patients With Metastatic Castration-Resistant Prostate Cancer
Recruitment Recruiting
Gender male
Phase Phase Ib/II
Variant Requirements No
Sponsors Regeneron Pharmaceuticals

prostate adenocarcinoma



Cemiplimab + REGN4336

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.